AI firms and pharma companies discuss drug development partnerships
What happened
Executives from traditional pharmaceutical companies and AI firms discussed the accelerating role of artificial intelligence in drug development. Isomorphic Labs, which raised US$5 billion in funding, has partnerships with drugmakers including Novartis and Merck & Co. Demis Hassabis, CEO of Isomorphic Labs, stated the company aims to have a drug in trials by the end of 2026, potentially faster than traditional timelines.
From businesstimes.com.sg
Why it matters
The rapid growth and investment in AI drug discovery firms are putting pressure on established pharmaceutical companies. Charl van Zyl, CEO of H Lundbeck, noted that while his company partners with AI firms to boost research and development productivity, there is a risk that these tech companies could become competitors over time.
From businesstimes.com.sg
Who's involved
- Demis HassabisCEO of Isomorphic Labs, driving the company's AI drug discovery mission
- NovartisPharmaceutical corporation partnering with Isomorphic Labs in drug development
- Charl van ZylCEO of H Lundbeck, commenting on the strategic shift toward AI partnerships
- Isomorphic LabsAI company that raised $5 billion and secured partnerships with drugmakers
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Isomorphic LabsSpeculative
Could see increased investment funding due to its $5 billion raise and major partnerships, accelerating research and development.
Keep exploring
The entities involved
-
Demis Hassabis
British artificial intelligence researcher (born 1976)
Nothing else this week.
-
Novartis
Swiss-American multinational pharmaceutical corporation
Nothing else this week.